Fort Washington Investment Advisors Inc. OH Decreases Stake in Progyny, Inc. $PGNY

Key Points

• Fort Washington Investment Advisors Inc. OH reduced its stake in Progyny, Inc. by 1.4% during the second quarter, owning 1,244,163 shares valued at approximately $27.37 million.
• Progyny reported $0.19 earnings per share for the last quarter, missing the consensus estimate of $0.42, despite revenues increasing by 9.5% year-over-year to $332.87 million.
• Analysts have recently upgraded Progyny's stock ratings, with a target price ranging from $23.00 to $28.00, indicating a positive outlook for the company.

Fort Washington Investment Advisors Inc. OH lessened its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 1.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,244,163 shares of the company's stock after selling 17,317 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned 1.45% of Progyny worth $27,372,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its position in Progyny by 38.4% during the 4th quarter. Nuveen Asset Management LLC now owns 295,979 shares of the company's stock worth $5,106,000 after purchasing an additional 82,087 shares during the period. GAMMA Investing LLC raised its holdings in shares of Progyny by 7,359.2% during the 1st quarter. GAMMA Investing LLC now owns 120,167 shares of the company's stock valued at $2,685,000 after buying an additional 118,556 shares during the period. NBC Securities Inc. raised its holdings in shares of Progyny by 97,037.5% during the 1st quarter. NBC Securities Inc. now owns 23,313 shares of the company's stock valued at $520,000 after buying an additional 23,289 shares during the period. Olstein Capital Management L.P. acquired a new position in Progyny during the 1st quarter worth approximately $469,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Progyny in the 1st quarter worth approximately $354,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Price Performance

PGNY opened at $21.46 on Monday. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76. The stock has a market capitalization of $1.85 billion, a PE ratio of 36.37, a P/E/G ratio of 1.83 and a beta of 1.33. The firm's fifty day moving average price is $22.79 and its 200 day moving average price is $22.27.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The company had revenue of $332.87 million during the quarter, compared to the consensus estimate of $315.70 million. During the same period in the previous year, the firm posted $0.17 EPS. Progyny's revenue for the quarter was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Insider Activity at Progyny

In related news, Director Kevin K. Gordon sold 2,500 shares of the firm's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the transaction, the director directly owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Allison Swartz sold 2,398 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the sale, the executive vice president owned 79,697 shares of the company's stock, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,895 shares of company stock valued at $179,311. Insiders own 9.40% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Leerink Partners upgraded shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price objective on the stock in a research note on Tuesday, July 8th. Wall Street Zen raised shares of Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Leerink Partnrs upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $28.00 price objective (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Finally, Canaccord Genuity Group lifted their target price on Progyny from $21.00 to $23.00 and gave the stock a "hold" rating in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $25.44.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.